Mesenchymal stem cells may slow the progression of amyotrophic lateral sclerosis by suppressing neuroinflammation through the induction of regulatory T cells, according to a peer-reviewed review published in the Journal of Translational Medicine. Authors Thomas E. Ichim and Neil H. Riordan evaluate the therapeutic potential of cellular immunomodulation against amyotrophic lateral sclerosis, which remains a uniformly fatal motor neuron disease. While neuroinflammation is recognized as a key contributor to disease progression, clinically effective immune-modulating therapies for the condition have remained limited.
The review notes that widespread clinical enthusiasm for stem cell therapy has historically centered on tissue regeneration and rejuvenation. However, the authors point out that the initial Food and Drug Administration approval granted for mesenchymal stem cells was established for immune modulation in graft-versus-host disease, rather than for structural tissue repair. Drawing on this immunomodulatory foundation, the analysis focuses on the biological mechanisms through which mesenchymal stem cells influence immune pathways, emphasizing how the generation and expansion of regulatory T cells could counteract neuroinflammatory activity in motor neuron disorders.
Despite the biological rationale for cell-based immunotherapy, clinical results observed to date in amyotrophic lateral sclerosis trials have been mixed.
To overcome these mixed clinical outcomes, the authors argue for the integration of prospective biomarker monitoring within future therapeutic strategies. Implementing systematic tracking of immune and blood-based biomarkers could sharpen clinical protocols by refining patient selection criteria, directing the selection of optimal cell types and adjuvants, and properly calibrating treatment intensity.
Ultimately, the review concludes that regulatory T cells induced by mesenchymal stem cells represent a promising immunomodulatory mechanism to mitigate neuroinflammation and slow disease progression in amyotrophic lateral sclerosis.
Subject of Research: Mesenchymal stem cell therapy and regulatory T cell modulation in amyotrophic lateral sclerosis
Article Title: Immunological aspects of mesenchymal stem cell therapy for ALS
Article References: Ichim, T. E., & Riordan, N. H. (2026). Immunological aspects of mesenchymal stem cell therapy for ALS. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09086-x
Image Credits: AI Generated
DOI: 10.1186/s12967-026-09086-x
Keywords: Amyotrophic lateral sclerosis, Mesenchymal stem cells, Regulatory T cells, Neuroinflammation, Immunomodulation, Biomarkers, Translational medicine, Clinical trials, Immunological, aspects, mesenchymal, stem
News Source: Drew Townsend. (November 9, 2026). Review Evaluates Mesenchymal Stem Cell Immune Modulation to Slow ALS Progression. Scienmag.



